康方生物(9926.HK,股价92.3港元,市值828.46亿港元)双抗药物依沃西又一次在头对头试验中战胜了PD-1,这次的对手是百济神州(688235.SH)的替雷利珠单抗。4月23日早间,康方生物宣布依沃西联合化疗对比替雷利珠单抗联合化疗一线治疗晚期鳞状非小细胞肺癌(sq-NSCLC)的注册性III期头对头临床研究(AK112-306/HARMONi-6),经独立数据监察委员会(IDMC)评估...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.